ENTA NASDAQ
Credit Risk of going bust: lower than 56% of companies Debt: 13.7% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.18 (down 98%), Enanta Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $55.7M against a stock market value of $349.5M.
Distance to default 5.75 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $27.8M (short-term plus half of long-term), stock volatility 47.7%; Altman Z'' -2.23. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Watertown, MA 02472
US
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Rottinghaus Scott T. | F-InKind | 1,467 | $13.34 | 2026-08-08 |
| Vance Terry | A-Award | 20,000 | $14.17 | 2026-03-11 |
| Russell Lesley | A-Award | 20,000 | $14.17 | 2026-03-11 |
| Peterson Kristine | A-Award | 20,000 | $14.17 | 2026-03-11 |
| Hata Yujiro S | A-Award | 20,000 | $14.17 | 2026-03-11 |